Сравнение

Pasireotid vs. Teduglutid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

396091-73-9

197922-42-2

Молекулярная масса

1047.21 g/mol

3752.13 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Teduglutid

Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Pasireotid	Teduglutid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Pasireotid and Teduglutid?: Pasireotid is classified as "Исследования (прочее)", while Teduglutid is classified as "Исследования (прочее)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Teduglutid?: The highest available evidence level is "РКИ на людях" for Pasireotid and "РКИ на людях" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Teduglutid in Germany and the United States?: Германия: Pasireotid — Рецептурный, Teduglutid — Рецептурный. США: Pasireotid — Рецептурный, Teduglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Teduglutid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Pasireotid and Teduglutid?

Pasireotid is classified as "Исследования (прочее)", while Teduglutid is classified as "Исследования (прочее)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Teduglutid?

The highest available evidence level is "РКИ на людях" for Pasireotid and "РКИ на людях" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Teduglutid in Germany and the United States?

Германия: Pasireotid — Рецептурный, Teduglutid — Рецептурный. США: Pasireotid — Рецептурный, Teduglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.